Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for PatientsGlobeNewsWire • 07/20/23
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated CirrhosisGlobeNewsWire • 07/18/23
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPDGlobeNewsWire • 05/11/23
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye DiseasePRNewsWire • 03/06/23
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1PRNewsWire • 11/03/22
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive ChairpersonPRNewsWire • 10/03/22
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and PathogensGlobeNewsWire • 09/15/22
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for CanadaPRNewsWire • 09/07/22
GigaGen Publishes Research Showcasing First-Ever Clinical GMP Manufacturing and IND-Enabling Studies for its New Class of Drugs, Recombinant Polyclonal AntibodiesGlobeNewsWire • 07/28/22
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and BeyondThe Motley Fool • 05/26/22